RNA-delivery is a promising tool to develop therapies for difficult to treat diseases such as neurological disorders, by silencing pathological genes or expressing therapeutic proteins. However, in many cases RNA delivery requires a vesicle that could effectively protect the molecule from bio-degradation, bypass barriers i.e., the blood brain barrier, transfer it to a targeted tissue and efficiently release the RNA inside the cells. Many vesicles such as viral vectors, and polymeric nanoparticles have been mentioned in literature. In this review, we focus in the discussion of lipid-based advanced RNA-delivery platforms. Liposomes and lipoplexes, solid lipid nanoparticles and lipid nanoparticles are the main categories of lipidic platforms for RNA-delivery to the central nervous systems (CNS). A variety of surface particles' modifications and routes of administration have been studied to target CNS providing encouraging results . It is concluded that lipid-based nanoplatforms will play a key role in the development of RNA neuro-therapies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9395673 | PMC |
| http://dx.doi.org/10.3389/fphar.2022.900610 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
High-density lipoprotein nanoparticles spontaneously target to damaged renal tubules and alleviate renal fibrosis by remodeling the fibrotic niches.
Nat Commun
January 2025
College of Polymer Science and Engineering, West China School of Public Health, Med-X center of materials, Sichuan University, Chengdu, Sichuan, 610065, China.
Chronic kidney disease (CKD) ultimately causes renal fibrosis and end-stage renal disease, thus seriously threatens human health. However, current medications for CKD and fibrosis are inefficient, which is often due to poor targeting capability to renal tubule. In this study, we discover that biomimetic high-density lipoprotein (bHDL) lipid nanoparticles possess excellent targeting ability to injured tubular epithelial cells by kidney injury molecule-1(KIM-1) mediated internalization.
View Article and Find Full Text PDFEnhanced Anticancer Efficiency of Curcumin Co-Loaded Lawsone Solid Lipid Nanoparticles Against MCF-7 Breast Cancer Cell Lines: Optimization by Statistical JMP Software-Based Experimental Approach.
Assay Drug Dev Technol
January 2025
Department of Pharmaceutics, Raghavendra Institute of Pharmaceutical Education & Research - Autonomous, Anantapur, Andhra Pradesh, India.
Reducing off-target expression of mRNA therapeutics and vaccines in the liver with microRNA binding sites.
Mol Ther Methods Clin Dev
March 2025
Department of Medicine, Division of Infectious Diseases, Mayo Clinic, Rochester, MN 55902, USA.
Lipid nanoparticles (LNPs) are often liver tropic, presenting challenges for LNP-delivered mRNA therapeutics intended for other tissues, as off-target expression in the liver may increase side effects and modulate immune responses. To avoid off-target expression in the liver, miR-122 binding sites have been used by others in viral and non-viral therapeutics. Here, we use a luciferase reporter system to compare different copy numbers and insertion locations of miR-122 binding sequences to restrict liver expression.
View Article and Find Full Text PDFSelection strategy for encapsulation of hydrophilic and hydrophobic ingredients with food-grade materials: A systematic review and analysis.
Food Chem X
January 2025
School of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai 200093, China.
Various lipid and biopolymer-based nanocarriers have been developed to encapsulate food ingredients. The selection of nanocarrier type, preparation techniques, and loading methods should consider the compatibility of nutrient properties, nanocarrier composition, and product requirements. This review focuses on the loading methods for hydrophilic and hydrophobic substances, along with a detailed exploration of nanocarrier categorization, composition, and preparation methods.
View Article and Find Full Text PDFEnhanced antitumor efficacy of STING agonist MSA-2 by lipid nanoparticles delivering circular IL-23 mRNA and platinum-modified MSA-2 combination.
Mater Today Bio
February 2025
Institute of Reproductive Medicine, School of Medicine, Nantong University, Nantong, Jiangsu, 226000, China.
A next-generation STING agonist MSA-2 is a promising tumor immunotherapy strategy. However, the methods for improving the anti-tumor efficacy of MSA-2 are a lot of effort. We have demonstrated antitumor effect of platinum-modified MSA-2 (MSA-2-Pt) was better than MSA-2.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!